FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Insulin | Lantus | Pediatrics